Akebia Therapeutics (AKBA) Stock: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$0.95
0.01 (0.55%)
â˛
5d:
-3.21%
30d:
+6.55%
90d:
+5.81%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: AKBA is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: AKBA is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $0.95, which is considered fair relative to its 30-day fair value range of $0.83 to $1.09. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.9) compared to its historical average (12.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AKBA is in a downtrend. Immediate support is located at $0.85, while resistance sits at $1.05.
Market Sentiment: AKBA scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.80 (+299.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AKBA is in a downtrend. Immediate support is located at $0.85, while resistance sits at $1.05.
Market Sentiment: AKBA scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.80 (+299.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.83 -
$1.09
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
Protect Your Profits
Holding AKBA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 299.3% below Wall St target ($3.80)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.83 -
$1.09
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.86
Resistance Level
$1.05
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.88
Wall Street Target
$3.80
(+299.3%)
Revenue Growth (YoY)
-21.4%
Profit Margin
-13.5%
PE vs Historical
-2.9 vs 12.4
CHEAP
Share & Embed Analysis
Last updated: September 13, 2026 3:08 PM ET
Data refreshes hourly during market hours. Next update: 4:08 PM
Data refreshes hourly during market hours. Next update: 4:08 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
